79 related articles for article (PubMed ID: 19745592)
21. Bendamustine: a novel cytotoxic agent for hematologic malignancies.
Blumel S; Goodrich A; Martin C; Dang NH
Clin J Oncol Nurs; 2008 Oct; 12(5):799-806. PubMed ID: 18842536
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors].
Ohtake T; Yasuda M; Watanabe K; Ito T; Ito J; Miyamoto K; Yoshida S; Abe N; Ishigame T; Ishii M; Kimijima I; Takenoshita S
Gan To Kagaku Ryoho; 2009 Sep; 36(9):1459-63. PubMed ID: 19755813
[TBL] [Abstract][Full Text] [Related]
23. Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer.
Tanaka S; Nohara T; Iwamoto M; Sumiyoshi K; Kimura K; Takahashi Y; Tanigawa N
Cancer Chemother Pharmacol; 2009 Jul; 64(2):341-6. PubMed ID: 19039589
[TBL] [Abstract][Full Text] [Related]
24. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
Powell S; Dudek AZ
Anticancer Res; 2009 Oct; 29(10):4189-93. PubMed ID: 19846971
[TBL] [Abstract][Full Text] [Related]
25. Bendamustine therapy in chronic lymphocytic leukemia.
Masiello D; Tulpule A
Expert Opin Pharmacother; 2009 Jul; 10(10):1687-98. PubMed ID: 19527193
[TBL] [Abstract][Full Text] [Related]
26. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.
Leoni LM; Bailey B; Reifert J; Bendall HH; Zeller RW; Corbeil J; Elliott G; Niemeyer CC
Clin Cancer Res; 2008 Jan; 14(1):309-17. PubMed ID: 18172283
[TBL] [Abstract][Full Text] [Related]
27. The reawakening of bendamustine - also in breast cancer?
von Minckwitz G; Linder M; Loibl S
Onkologie; 2009 Sep; 32(8-9):462-3. PubMed ID: 19745588
[No Abstract] [Full Text] [Related]
28. Overcoming drug resistance in patients with metastatic breast cancer.
Wong ST; Goodin S
Pharmacotherapy; 2009 Aug; 29(8):954-65. PubMed ID: 19637949
[TBL] [Abstract][Full Text] [Related]
29. [The efficacy of S-1 monotherapy as a 2nd/3rd-line therapy for unresectable recurrent colon cancer: Kanagawa conference of clinical oncology (KCCO)].
Yokoyama T; Tokuhara H; Egawa T; Hashimoto O; Seki H; Koyanagi K; Bessho T
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1667-70. PubMed ID: 19838025
[TBL] [Abstract][Full Text] [Related]
30. "Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer.
Agrawal A; Robertson JF; Cheung KL
World J Surg Oncol; 2006 Jul; 4():40. PubMed ID: 16822312
[TBL] [Abstract][Full Text] [Related]
31. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.
Shayne M; Culakova E; Wolff D; Poniewierski MS; Dale DC; Crawford J; Lyman GH
Cancer; 2009 Nov; 115(22):5319-28. PubMed ID: 19672945
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy of treatment with high-dose toremifene in patients with metastatic breast cancer resistant to aromatase inhibitor treatment].
Niikura N; Kimura M; Kobayashi Y; Asahara F; Hayashi K; Shibata S; Shintoku J
Gan To Kagaku Ryoho; 2009 Jun; 36(6):1013-6. PubMed ID: 19542727
[TBL] [Abstract][Full Text] [Related]
33. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
34. Bendamustine: a new therapeutic option for hematologic malignancies.
Cheson BD
Clin Adv Hematol Oncol; 2008 Sep; 6(9):631-3. PubMed ID: 18827785
[No Abstract] [Full Text] [Related]
35. Factors associated with improved outcome after surgery in metastatic breast cancer patients.
McGuire KP; Eisen S; Rodriguez A; Meade T; Cox CE; Khakpour N
Am J Surg; 2009 Oct; 198(4):511-5. PubMed ID: 19800458
[TBL] [Abstract][Full Text] [Related]
36. Identification and quantitation of the N-acetyl-L-cysteine S-conjugates of bendamustine and its sulfoxides in human bile after administration of bendamustine hydrochloride.
Teichert J; Sohr R; Hennig L; Baumann F; Schoppmeyer K; Patzak U; Preiss R
Drug Metab Dispos; 2009 Feb; 37(2):292-301. PubMed ID: 18971319
[TBL] [Abstract][Full Text] [Related]
37. [Hormonal therapy with aromatase inhibitor in advanced breast cancer].
Vrbanec D; Belev B; Pavlinić-Diminić V; Pezerović D; Dusper B; Plestina S; Unusić J
Lijec Vjesn; 1998; 120(10-11):315-8. PubMed ID: 19658346
[TBL] [Abstract][Full Text] [Related]
38. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
[TBL] [Abstract][Full Text] [Related]
39. Bendamustine (Treanda) for CLL and NHL.
Med Lett Drugs Ther; 2008 Nov; 50(1299):91-2. PubMed ID: 19008789
[No Abstract] [Full Text] [Related]
40. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
